We put everyone's health and happiness first.
We are convinced that drug discovery to assure the well-being of human is a priority in today’s fast-paced society.
Despite the radical leap forward achieved in the IT field by the exploitation of innovative and creative items, the growth in the medical and life science sectors remains slow, especially when the rate of new drug launches is declining up to date.
Looking ahead DanDi BioScience is determined to overcome this issue and to provide healthcare solutions. The company provides an adequate hub for drug development by overlapping the knowledge of key executives, infection and immunology specialists, and development experts in one platform. Hence, speeding up the development of source technologies by carrying out the research responsibilities of individual pipelines.
People are always at the center of our priorities, and we will be always striving to met their health needs and their expectations and seeking their well-being and happiness. We promise to make every effort and to do our best, as respecting and loving people had been always the motive of treating diseases and the reason of DanDi BioScience’s growth.
183 publications Since last 5 years
30 SCI(E) publications (lead author)
25 PCT applications
Professor of Immunology, Konkuk Univ, Medical College
Director of Konkuk Univ, Life and Medical Science Institute
Chairman of Korean Society of Immunologists
Head of Korea Research Foundation of Basic Research Division (Medical department)
Review Member of Korea Health Industry Promotion Agency's Quality Certification (Biomedical field)
Person in charge of First-in-class Developing Project (Immunotherapeutics for Cancer, Korean Research Foundation)
Chairman of Medical Research Council (MRC, Ministry of Science and Technology )